Remdesivir (Veklury) authorized with conditions in Canada for severe COVID-19
In plain language
This is an advisory regarding the conditional authorization of the drug remdesivir (brand name Veklury) in Canada. Health Canada has authorized it for treating severe COVID-19 symptoms in adults and adolescents. This authorization comes with conditions for the manufacturer to ensure continued safety, efficacy, and quality.
What to do
- This is an advisory, not a recall requiring consumer action.
- Consult a healthcare professional for medical advice.
Get alerts for recalls like this
Get email alerts when new recalls affect products in this category.
Affected products
Specific affected products are listed in the official notice.
Do I have this product?
This recall applies to specific products. Details are listed in the official notice.
Frequently Asked Questions
Why was this product recalled?
This is an advisory regarding the conditional authorization of the drug remdesivir (brand name Veklury) in Canada. Health Canada has authorized it for treating severe COVID-19 symptoms in adults and adolescents. This authorization comes with conditions for the manufacturer to ensure continued safety, efficacy, and quality.
What should consumers do?
This is an advisory, not a recall requiring consumer action. Consult a healthcare professional for medical advice.
Where was the product sold?
This product was sold in Canada. For specific retailers or distribution areas, please check the official recall notice linked on this page.
Is there a health risk?
A potential safety risk has been identified with this product. Stop using it immediately and follow the instructions in the official recall notice.
When was this product recalled?
This product was recalled on July 28, 2020.
Is the Veklury brand affected by this recall?
Yes, Veklury products are affected by this recall. This is an advisory regarding the conditional authorization of the drug remdesivir (brand name Veklury) in Canada. Health Canada has authorized it for treating severe COVID-19 symptoms in adults and adolescents. This authorization comes with conditions for the manufacturer to ensure continued safety, efficacy, and quality.